The largest database of trusted experimental protocols

Cilengitide

Manufactured by Bio-Techne
Sourced in United States

Cilengitide is a laboratory product offered by Bio-Techne. It is a cyclic peptide that inhibits the activity of certain integrins, which are cell surface receptors involved in cell adhesion and signaling. The core function of Cilengitide is to serve as a research tool for studying integrin-mediated cellular processes in various in vitro and in vivo applications.

Automatically generated - may contain errors

4 protocols using cilengitide

1

Multi-parameter Live Cell Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
Live Cell Imaging solution, Fluo4-AM, CellTracker Deep Red, pHrodo iFL Red STP Ester, NucBlue live cell nuclear stain, NucGreen dead cell nuclear stain, and LIVE/DEAD fixable aqua stain were obtained from Invitrogen. DAPI was from Sigma, and paraformaldehyde (4% in PBS) was obtained from Alfa Aesar. Human annexin V protein was from BD Biosciences, human C5a protein from Peprotech, human TGFβ1 from Miltenyi Biotec, and recombinant human IFNγ and recombinant truncated human vitronectin from Gibco. Cytochalasin D was from Cayman Chemicals, Bafilomycin A1 from Abcam, and Jasplakinolide from Santa Cruz. PSB0739, MRS2179, MRS2211, and cilengitide were all obtained from Tocris. ADP, BSA, and crystal violet were from Sigma.
+ Open protocol
+ Expand
2

Rat Neonatal H9c2 Cardiac Myoblast Cell Line Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The rat neonatal H9c2 cardiac myoblast cell line was obtained from the Korea Cell Line Bank (Seoul, Korea). The cells were cultured in Dulbecco’s modified Eagles medium (DMEM)/high glucose with 10% fetal bovine serum and 1% penicillin-streptomycin (Corning/Mediatech, Inc., Manassas, VA, USA,).
DOX was purchased from Tocris Bioscience (Cat#2252, Bristol, UK). LY294002 (Cat#1130), the PI3K inhibitors, cilengitide (Cat#5870), and losartan potassium (Cat#3798), the integrin inhibitors αvβ3 and αvβ5, and the angiotensin II type 1 receptor (AT1R) inhibitors respectively, were purchased from Tocris Bioscience. The ILK inhibitor Cpd22 (Cat#407331) was obtained from EMD Millipore Corp. (Darmstadt, Germany). The survivin inhibitor YM-155 was purchased from MedChem Express (Cat#HY-10194, Monmouth Junction, NJ, USA).
+ Open protocol
+ Expand
3

Signaling Mechanisms of suPAR in Podocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant suPAR was purchased from R&D Systems (Minneapolis, MN, USA) and was added to cell culture media at a final concentration of 10 ng/mL. FMLF and cilengitide were obtained from Tocris (Minneapolis, MN, USA). Both were used at a final concentration of 1 µM. Pertussis toxin (PTX) was obtained from Sigma-Aldrich (Saint Louis, MO, USA). WRW4 was obtained from Abcam (Boston, MA, USA). Agonists were applied for 24 h or for 60 min. Nearly all previous studies on suPAR signaling in podocytes have utilized a 24 h exposure [9 (link),20 (link),21 (link)]. By contrast, GPCR signaling through G proteins (as opposed to arrestins) almost always operates over a much shorter time scale often in the range of seconds to minutes. We utilized 60 min exposures to allow sufficient time for ROS accumulation in the cytosol.
+ Open protocol
+ Expand
4

Peptide-Based Cell Adhesion Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
See Feinstein 2024a for constructs (Data File S1) and materials and methods. Calculations and graphs were made in GraphPad Prism. Mean and standard deviations were derived in Excel; See Feinstein 2024a (Data File S2) for details.
Peptides synthesized from GenScript. RGD purchased from R&D systems, #7723/10mg. Cilengitide purchased from Tocris, #5870.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!